Breaking News

Biden’s buprenorphine backtrack, Medicaid mudslinging, and Lilly’s insulin pricing fallout

March 2, 2023
Reporter, D.C. Diagnosis Writer

Good morning and happy Thursday, D.C. Diagnosis readers! I'm going to remind you once more that time is running out to snag a spot at our D.C. event — and acting White House science advisor Francis Collins is a recent addition to the agenda. It's next Tuesday. Be there or be square! As usual, I'm at rachel.cohrs@statnews.com and my mailbox is always open. 

addiction crisis

Biden's buprenorphine backtrack

Addiction doctors, public health experts, and even some congressional Democrats are up in arms about a new Biden administration proposal that would roll back Covid-era flexibilities surrounding the prescribing of buprenorphine, a key drug used to treat opioid addiction, my colleague Lev Facher writes

The new regulation would require that patients prescribed buprenorphine via telemedicine show up for an in-person evaluation within 30 days if they want to keep taking the medication. Addiction doctors, however, argue that they've issued both new prescriptions and refills via telemedicine for years now — largely without issue. And while the DEA says the regulation is aimed "at ensuring patient safety," its opponents say any limitation to buprenorphine access will have the opposite effect, leading people cut off from buprenorphine to return to illicit drug use. 

The move represents "a step in the wrong direction," Rep. Paul Tonko (D-N.Y.) told Lev. While the Covid-era flexibilities "opened the doors to recovery for millions," he added, "the DEA's proposal mandating an in-person follow up for telehealth patients using buprenorphine threatens to shut the doors once again." Read more here. 


insurance

Same drug, same patient, same insurer — coverage denied

Utilization management can be a jargon-y term that makes most people's eyes glaze over, but it has real implications for patients. My colleague Tara Bannow tells the powerful story of a patient who required an infusion medication to manage her rare kidney disease. 

The first time she needed the medication, Blue Cross Blue Shield of Massachusetts covered it, no questions asked. The medication helped her, and her disease went into remission for years. But when the disease reared its head again, the insurer refused to pay and sent her three denials.

Tara's reporting seems to have gotten results — the day after she called up the insurer, they suddenly decided to cover the infusions after all. Read the full story here.


budget battles

Medicaid mudslinging continues

Roughly a week out from the start of federal budget battles, Democrats and Republicans are ratcheting up accusations that the other party would take health care away from millions or slash their benefits. 

President Joe Biden in a Tuesday speech warned that "MAGA Republicans" want to "do away with the Affordable Care Act." Democratic lawmakers amped that message Wednesday, with leadership from both the Senate and House arguing in a press briefing that their GOP counterparts would gut Medicaid and relaunch attempts to repeal ACA (though many in the GOP caucus abandoned that plan after multiple failed attempts during the Trump administration). Meanwhile House Republican committee leaders in a statement accused Biden of "fearmongering" and actually spearheading efforts to kick people out of ACA coverage.

So what's really happening? Everyone is getting ready to make their pitch, since Biden's budget is due out next week. It's clear that Biden is readying his case for what he knows will be some controversial policies ("I want to make it clear, I'm gonna raise some taxes out there") by making the populist argument that things like tax hikes — which he says will target billionaires — will protect health care access and reduce the deficit along the way. Republicans say they want to balance the budget in a decade, which would take significant spending cuts, it's just a matter of where. 



drug pricing

Lilly's insulin pricing announcement makes waves

D3 vis exported to PNG (2)Rachel Cohrs/STAT

Eli Lilly's announcement that it will slash prices for some of its most popular insulin products and reduce costs for insured patients to $35 per month created shockwaves in Washington and on Wall Street. 

Unlike Lilly's snafu last year with a fake Twitter post promising free insulin, the new price cuts were a boon to its stock price on Wednesday. The company's stock price ended the day more than $4 higher than it started. 

The announcement drew praise from President Biden, who called on other manufacturers to follow suit. Senate health committee Chair Bernie Sanders (I-Vt.) also sent letters to Sanofi and Novo Nordisk asking them to follow Eli Lilly's lead. Insulin pricing patient advocate Laura Marston celebrated too, but also cautioned that the move is voluntary and can be undone at any moment, that the reductions still put prices in the U.S. higher than other countries, and that it proves that Lilly could have chosen to lower prices a long time ago. 


reproductive health

A HIPAA abortion loophole

Keeping patient data private in a post-Roe world is a challenge beyond what HIPAA was designed to handle, Avani Kalra writes for STAT

It turns out that the law offers little protection if law enforcement requests a person's medical record. Rep. Anna Eshoo (D-Calif.) is leading a bill that would require patient consent before sharing information related to abortion or pregnancy loss to close the gap, but it's unlikely to advance in a Republican-led House. 

There may be other options to offer more protection without Congress, which Avani outlines in the full story


personnel

On the move

Two health care policy hires caught our eye this week, one on each side of the aisle. Families USA's Eliot Fishman is headed to CMMI's senior leadership team to work on payment and delivery reform, and former Trump White House official and Sen. Pat Toomey aide Theo Merkel is headed to Brian Blase's Paragon Health Institute to work on private health reform.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • New head of FDA's neuroscience office takes over at crucial time, STAT
  • Former GOP Sen. James Inhofe retired because of long COVID symptoms. Other colleagues have it but keep it secret, he said, Insider
  • Facebook, TikTok, and proteins: Why big tech companies are betting on AI protein design, STAT
  • DeSantis is championing medical freedom. GOP state lawmakers like what they see, Politico
  • Opinion: HHS's Environmental Justice Index institutionalizes climate apartheid, STAT

Thanks for reading! More next week,


Enjoying D.C. Diagnosis? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments